AP766A - A vaccine based on hepatitis B antigen. - Google Patents

A vaccine based on hepatitis B antigen. Download PDF

Info

Publication number
AP766A
AP766A APAP/P/1997/001060A AP9701060A AP766A AP 766 A AP766 A AP 766A AP 9701060 A AP9701060 A AP 9701060A AP 766 A AP766 A AP 766A
Authority
AP
ARIPO
Prior art keywords
hepatitis
vaccine
hbsag
antigen
vaccine composition
Prior art date
Application number
APAP/P/1997/001060A
Other languages
English (en)
Other versions
AP9701060A0 (en
Inventor
Pierre Hauser
Nathalie Marie-Josephe Claude Garcon-Johnson
Pierre Michel Desmons
Original Assignee
Smithkline Biologicals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10770292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP766(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Biologicals S A filed Critical Smithkline Biologicals S A
Publication of AP9701060A0 publication Critical patent/AP9701060A0/xx
Application granted granted Critical
Publication of AP766A publication Critical patent/AP766A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
APAP/P/1997/001060A 1995-02-25 1996-02-15 A vaccine based on hepatitis B antigen. AP766A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9503863.4A GB9503863D0 (en) 1995-02-25 1995-02-25 Vaccine compositions
PCT/EP1996/000681 WO1996026741A1 (en) 1995-02-25 1996-02-15 Hepatitis b vaccine

Publications (2)

Publication Number Publication Date
AP9701060A0 AP9701060A0 (en) 1997-10-31
AP766A true AP766A (en) 1999-09-17

Family

ID=10770292

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001060A AP766A (en) 1995-02-25 1996-02-15 A vaccine based on hepatitis B antigen.

Country Status (35)

Country Link
US (1) US5972346A (de)
EP (1) EP0810877B1 (de)
JP (1) JP3881015B2 (de)
KR (1) KR100365373B1 (de)
CN (1) CN1101225C (de)
AP (1) AP766A (de)
AR (1) AR002279A1 (de)
AT (1) ATE209045T1 (de)
AU (1) AU695921B2 (de)
BG (1) BG101851A (de)
BR (1) BR9607458A (de)
CA (1) CA2212552C (de)
CZ (1) CZ288417B6 (de)
DE (1) DE69617211T2 (de)
DK (1) DK0810877T3 (de)
EA (1) EA199700126A1 (de)
ES (1) ES2166879T3 (de)
FI (1) FI118118B (de)
GB (1) GB9503863D0 (de)
HU (1) HU224832B1 (de)
IL (1) IL117249A (de)
MA (1) MA23814A1 (de)
MX (1) MX9706450A (de)
MY (1) MY113428A (de)
NO (1) NO319394B1 (de)
NZ (1) NZ302674A (de)
OA (1) OA10612A (de)
PL (1) PL182679B1 (de)
PT (1) PT810877E (de)
SA (1) SA96160633B1 (de)
SK (1) SK115097A3 (de)
TR (1) TR199700849T1 (de)
TW (1) TW467745B (de)
WO (1) WO1996026741A1 (de)
ZA (1) ZA961460B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620414B2 (en) * 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6488934B1 (en) * 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
US20010014331A1 (en) * 1996-11-07 2001-08-16 Smithkline Beecham Biologicals S.A. Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
US20030049268A1 (en) 1998-05-01 2003-03-13 Smithkline Beecham Biologicals S.A. Novel composition
GB9809507D0 (en) * 1998-05-01 1998-07-01 Smithkline Beecham Biolog Novel composition
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
DE122007000087I1 (de) * 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
AU2212100A (en) * 1998-12-23 2000-07-12 Merck & Co., Inc. Improved recombinant hepatitis b surface antigen
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
JP2008530195A (ja) * 2005-02-16 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド リン酸アルミニウムおよび３ｄ−ｍｐｌを含むアジュバント組成物
AP2745A (en) * 2005-08-02 2013-09-30 Novartis Vaccines & Diagnostic Reducing interference between oil-containing adjuvants and surfactant-containing antigens
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
PL1951299T3 (pl) 2005-11-04 2012-07-31 Novartis Ag Szczepionki przeciw grypie zawierające kombinacje adiuwantów cząsteczkowych i czynników wzmacniających immunogenność
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
CN100415294C (zh) * 2005-12-23 2008-09-03 中国农业大学 一种治疗和/或预防乙肝的药物
KR20080089663A (ko) 2006-01-27 2008-10-07 노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
EP1862176A1 (de) * 2006-05-31 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
EP1862177A1 (de) * 2006-06-01 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008032219A2 (en) 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
HRP20120790T1 (hr) 2007-06-27 2013-01-31 Novartis Ag Cjepiva protiv influence sa niskom koliäśinom aditiva
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009081172A1 (en) 2007-12-24 2009-07-02 Novartis Ag Assays for adsorbed influenza vaccines
PL3178490T3 (pl) 2009-07-15 2022-08-01 Glaxosmithkline Biologicals S.A. Kompozycje białka f rsv i sposoby ich wytwarzania
PL2667892T3 (pl) 2011-01-26 2019-09-30 Glaxosmithkline Biologicals Sa Schemat szczepień przeciwko rsv
US9452212B2 (en) 2011-04-14 2016-09-27 Dynavax Technologies Corporation Methods and compositions for eliciting an immune response against hepatitis B virus
ES2651143T3 (es) 2011-05-13 2018-01-24 Glaxosmithkline Biologicals Sa Antígenos de F de prefusión del VRS
AU2016281904B2 (en) 2015-06-26 2022-08-11 Seqirus UK Limited Antigenically matched influenza vaccines
WO2020099927A1 (en) 2018-11-13 2020-05-22 Variation Biotechnologies Inc. Immunogenic compositions for treatment of hepatitis b

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019780A1 (en) * 1992-03-27 1993-10-14 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a
WO1994021292A1 (en) * 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0414374B1 (de) * 1989-07-25 1997-10-08 Smithkline Biologicals S.A. Antigene sowie Verfahren zu deren Herstellung
ES2120449T3 (es) * 1991-05-29 1998-11-01 Origin Medsystems Inc Dispositivo de retraccion para la cirujia endoscopica.
JP3626996B2 (ja) * 1992-05-23 2005-03-09 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム Ｂ型肝炎表面抗原および他の抗原からなる複合ワクチン
GB9311536D0 (en) * 1993-06-04 1993-07-21 Unilever Plc Hot soluble low density extractable food product

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019780A1 (en) * 1992-03-27 1993-10-14 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a
WO1994021292A1 (en) * 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a

Also Published As

Publication number Publication date
SK115097A3 (en) 1998-02-04
EP0810877B1 (de) 2001-11-21
DK0810877T3 (da) 2002-02-25
FI118118B (fi) 2007-07-13
ES2166879T3 (es) 2002-05-01
CZ267497A3 (cs) 1998-02-18
AR002279A1 (es) 1998-03-11
NO973873D0 (no) 1997-08-22
JP3881015B2 (ja) 2007-02-14
HUP9801242A1 (hu) 1998-08-28
GB9503863D0 (en) 1995-04-19
JPH11501018A (ja) 1999-01-26
CZ288417B6 (en) 2001-06-13
KR100365373B1 (ko) 2003-07-07
KR19980702480A (ko) 1998-07-15
FI973457L (fi) 1997-08-22
NO319394B1 (no) 2005-08-08
OA10612A (en) 2002-08-29
EP0810877A1 (de) 1997-12-10
HK1004117A1 (en) 1998-11-20
MY113428A (en) 2002-02-28
WO1996026741A1 (en) 1996-09-06
ZA961460B (en) 1996-08-29
CA2212552A1 (en) 1996-09-06
US5972346A (en) 1999-10-26
NO973873L (no) 1997-08-22
HUP9801242A3 (en) 2000-08-28
EA199700126A1 (ru) 1998-02-26
CA2212552C (en) 2006-07-11
HU224832B1 (en) 2006-03-28
PT810877E (pt) 2002-04-29
AU695921B2 (en) 1998-08-27
NZ302674A (en) 1999-01-28
AP9701060A0 (en) 1997-10-31
TR199700849T1 (xx) 1998-01-21
BG101851A (en) 1998-04-30
CN1101225C (zh) 2003-02-12
FI973457A0 (fi) 1997-08-22
BR9607458A (pt) 1998-06-30
MX9706450A (es) 1998-07-31
PL321966A1 (en) 1998-01-05
DE69617211D1 (en) 2002-01-03
AU4878096A (en) 1996-09-18
ATE209045T1 (de) 2001-12-15
PL182679B1 (pl) 2002-02-28
IL117249A0 (en) 1996-06-18
CN1176604A (zh) 1998-03-18
IL117249A (en) 2000-11-21
MA23814A1 (fr) 1996-10-01
DE69617211T2 (de) 2002-07-25
TW467745B (en) 2001-12-11
SA96160633B1 (ar) 2005-10-15

Similar Documents

Publication Publication Date Title
AP766A (en) A vaccine based on hepatitis B antigen.
CA2132833C (en) Hepatitis vaccines containing 3-o-deacylated monophosphoryl lipid a
HK1003218B (en) Hepatitis vaccins containing 3-0 deacylated monophosphoryl lipid a
HK1045935A1 (en) Vaccine composition containing 3-O deacylated monophosphoryl ester A
US6488934B1 (en) Hepatitis B vaccine
US6620414B2 (en) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
KR20010043224A (ko) 백신 조성물
HK1004117B (en) Hepatitis b vaccine
HK1011930C (en) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
HK1011930B (en) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
HK1023499B (en) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a